The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
V. Verschaeve
No relevant relationships to disclose
L. A. D'Hondt
No relevant relationships to disclose
L. M. J. Verbeke
No relevant relationships to disclose
F. Van Fraeyenhove
No relevant relationships to disclose
S. Du Four
No relevant relationships to disclose
J. Duerinck
No relevant relationships to disclose
B. Neyns
Research Funding - Merck KGaA